Esperion will present two studies at AHA Scientific Sessions 2025, focusing on bempedoic acid and cardiovascular events.
Quiver AI Summary
Esperion announced that it will have an oral and a poster presentation at the AHA Scientific Sessions 2025 in New Orleans, scheduled for November 7-10, 2025. The oral presentation will focus on a secondary analysis of the CLEAR Outcomes trial concerning bempedoic acid monotherapy and its effects on LDL cholesterol and cardiovascular events. The poster presentation will analyze the effects of bempedoic acid on venous thromboembolism. Esperion's president and CEO, Sheldon Koenig, emphasized the trial's importance in addressing statin intolerance and supporting new treatment options for patients with elevated LDL-C. The company, known for its FDA-approved oral non-statin medications for cardiovascular disease, is advancing its research in developing new medicines, including targeting ATP citrate lyase inhibitors.
Potential Positives
- Esperion will present significant findings from the CLEAR Outcomes trial at the AHA Scientific Sessions 2025, highlighting their commitment to advancing cardiovascular health.
- The company's presentations showcase their innovative approach to addressing statin intolerance and expanding treatment options for patients with elevated LDL-C.
- Esperion is positioned as a leader in the biopharmaceutical industry with its FDA-approved oral, once-daily, non-statin medicines for patients at risk for cardiovascular disease, demonstrating its unique market offering.
Potential Negatives
- Presentation of results from the CLEAR Outcomes trial may draw attention to potential limitations or challenges associated with the company's products, such as issues related to statin intolerance.
- The need to expand treatment options for patients with elevated LDL-C suggests that current offerings may not be sufficient, highlighting a potential gap in the company's portfolio.
- The focus on a new generation of ATP citrate lyase inhibitors indicates a shift in strategy, which could imply concerns about the competitiveness or effectiveness of existing products in the market.
FAQ
What presentations will Esperion be giving at AHA Scientific Sessions 2025?
Esperion will present an oral presentation on bempedoic acid monotherapy and a poster on its effects on venous thromboembolism.
When will Esperion’s presentations take place?
The oral presentation is on November 9, 2025, from 9:45 – 11:00 AM CST, and the poster session is at 11:50 AM – 1:05 PM CST.
Who are the presenters from Esperion at the AHA sessions?
Carolina Pires Zingano, MD, will present the oral session, and Bernardo Frison Spiazzi, MD, will present the poster session.
What is the CLEAR Outcomes trial?
The CLEAR Outcomes trial is a significant study that examines the efficacy of bempedoic acid in reducing LDL cholesterol and cardiovascular events.
How does Esperion address issues of statin intolerance?
Esperion develops FDA-approved, non-statin oral medications for patients struggling with elevated LDL cholesterol and statin intolerance.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ESPR Insider Trading Activity
$ESPR insiders have traded $ESPR stock on the open market 9 times in the past 6 months. Of those trades, 0 have been purchases and 9 have been sales.
Here’s a breakdown of recent trading of $ESPR stock by insiders over the last 6 months:
- SHELDON L. KOENIG (President and CEO) has made 0 purchases and 2 sales selling 58,901 shares for an estimated $113,050.
- BENJAMIN LOOKER (General Counsel) has made 0 purchases and 4 sales selling 15,241 shares for an estimated $29,715.
- BENJAMIN HALLADAY (Chief Financial Officer) has made 0 purchases and 3 sales selling 14,286 shares for an estimated $28,125.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ESPR Hedge Fund Activity
We have seen 70 institutional investors add shares of $ESPR stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BELLEVUE GROUP AG removed 9,694,064 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $9,542,836
- MORGAN STANLEY removed 5,531,144 shares (-84.0%) from their portfolio in Q2 2025, for an estimated $5,444,858
- PENDERFUND CAPITAL MANAGEMENT LTD. added 4,676,519 shares (+233.8%) to their portfolio in Q2 2025, for an estimated $4,603,565
- TWO SEAS CAPITAL LP added 3,024,104 shares (+43.6%) to their portfolio in Q2 2025, for an estimated $2,976,927
- NUVEEN, LLC removed 2,665,087 shares (-86.3%) from their portfolio in Q2 2025, for an estimated $2,623,511
- MARSHALL WACE, LLP added 1,679,294 shares (+46.2%) to their portfolio in Q2 2025, for an estimated $1,653,097
- JPMORGAN CHASE & CO removed 1,360,311 shares (-70.8%) from their portfolio in Q2 2025, for an estimated $1,339,090
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ESPR Analyst Ratings
Wall Street analysts have issued reports on $ESPR in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 06/17/2025
- Needham issued a "Buy" rating on 05/07/2025
To track analyst ratings and price targets for $ESPR, check out Quiver Quantitative's $ESPR forecast page.
$ESPR Price Targets
Multiple analysts have issued price targets for $ESPR recently. We have seen 2 analysts offer price targets for $ESPR in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $16.0 on 09/19/2025
- Serge Belanger from Needham set a target price of $4.0 on 05/07/2025
Full Release
ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, LA, November 7-10, 2025.
Oral Presentation
Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events: a secondary analysis of the CLEAR Outcomes trial
November 9, 2025, 9:45 – 11:00 AM CST
Presenter: Carolina Pires Zingano, MD (Cleveland Clinic)
Poster Presentation
Effects of Bempedoic Acid on Venous Thromboembolism: a Post-Hoc Analysis of the CLEAR Outcomes trial
Moderated Digital Poster Session, VM.MDP.07 Top Clinical and Translational Abstracts in Vascular Medicine:
November 9, 2025, 11:50 AM – 1:05 PM CST
Presenter: Bernardo Frison Spiazzi, MD (Cleveland Clinic)
“The landmark CLEAR Outcomes trial continues to provide clinically meaningful insights that highlight the challenges of statin intolerance and reinforce the importance of expanding treatment options for patients at risk of cardiovascular events due to elevated LDL-C,” said Sheldon Koenig, president and CEO of Esperion.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms.
Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit esperion.com and follow Esperion on LinkedIn and X .
Esperion Contact Information:
Investors:
Alina Venezia
[email protected]
(734) 887-3903
Media:
Tiffany Aldrich
[email protected]
(616) 443-8438
